BACKGROUND The LHFRS is a simple score derived from three factors (history of hypertension, history of coronary artery disease/myocardial infarction, and red blood cell distribution width) deployed for the risk stratification of AHF in Greek population. This study aimed to validate the Larissa Heart Failure Risk Score (LHFRS) in patients with acute heart failure (AHF) in a Japanese population. METHODS We performed post-hoc analysis of 1670 consecutive patients enrolled in the REALITY-AHF. In all, 964 patients were finally enrolled. Exclusion criteria included patients with anemia, malignancies and sepsis. The primary outcome was defined as a composite of all-cause mortality and/or heart failure readmission, and the secondary outcome was defined as all-cause mortality. RESULTS The median admission LHFRS value was 1 (interquartile range [IQR]: 0-2). During a median follow-up of 365 (IQR: 161-365) days, the primary and secondary outcomes were observed in 321 and 157 patients, respectively. LHFRS was an independent predictor of both the primary (adjusted hazard ratio per 1-point increase, 95% confidence interval: 1.17 [1.04-1.32], p = 0.011), and the secondary outcomes (1.31 [1.12-1.55], p = 0.001). Patients with higher LHFRS scores (≥2) exhibited significantly worse outcomes than those with lower scores (<2) both for the primary outcome (1.40 [1.07-1.83], p = 0.014) and the secondary outcome (1.60 [1.09-2.34], p = 0.015). Additionally, LHFRS revealed an excellent goodness of fit (observed versus predicted outcomes) for predicting both the primary and the secondary outcomes (p > 0.99 and p = 0.99, respectively). CONCLUSION The simple LHFRS was proved as a reliable predictor of outcomes in patients with AHF.

中文翻译：

---

验证用于急性心力衰竭风险分层的拉里萨心力衰竭风险评分。

背景 LHFRS 是一个简单的评分，源自三个因素（高血压病史、冠状动脉疾病/心肌梗塞病史和红细胞分布宽度），用于希腊人群中 AHF 的风险分层。本研究旨在验证日本人群中急性心力衰竭 (AHF) 患者的拉里萨心力衰竭风险评分 (LHFRS)。方法 我们对参加 REALITY-AHF 的 1670 名连续患者进行了事后分析。最终，共有 964 名患者入组。排除标准包括患有贫血、恶性肿瘤和败血症的患者。主要结局定义为全因死亡率和/或心力衰竭再入院的复合结局，次要结局定义为全因死亡率。结果 入院中位 LHFRS 值为 1（四分位距 [IQR]：0-2)。在 365 (IQR: 161-365) 天的中位随访期间，分别在 321 和 157 名患者中观察到主要和次要结局。LHFRS 是主要结局（调整后的风险比每增加 1 点，95% 置信区间：1.17 [1.04-1.32]，p = 0.011）和次要结局（1.31 [1.12-1.55]，p = 0.001)。LHFRS 评分较高 (≥2) 的患者在主要结局 (1.40 [1.07-1.83], p = 0.014) 和次要结局 (1.60 [1.09-2.34] ) 方面的结局明显低于得分较低 (<2) 的患者, p = 0.015)。此外，LHFRS 揭示了预测主要和次要结果的出色拟合优度（观察结果与预测结果）（分别为 p > 0.99 和 p = 0.99）。